Glenmark Pharmaceuticals Ltd. (GLENMARK.NS)

NSE - NSE Delayed Price. Currency in INR
923.45+17.70 (+1.95%)
At close: 5:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close905.75
Bid923.45 x
Ask0.00 x
Day's Range898.55 - 926.55
52wk Range671.10 - 1,074.90
1y Target EstN/A
Market Cap259.76B
P/E Ratio (ttm)35.76
Avg Vol (3m)548,067
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters11 days ago

    GRAPHIC-Credit Suisse sees scope for UK mining dividend rise

    Dividend yields at British mining companies have hit a five-year low just as cash flows in the sector improve, prompting some analysts to call for higher payouts as early as next year. Free cash flow yield, a measure of balance sheet health, is poised to rise to 7.1 percent for major miners next year. Dividend yields are forecast to almost double to 3.6 percent, according to Credit Suisse.

  • Reuters7 months ago

    Indian court grants temporary relief to Abbott, Glenmark in drug ban case

    An Indian court on Tuesday granted interim injunction to U.S. drugmaker Abbott's India unit , and domestic companies Glenmark Pharmaceuticals and Macleods Pharmaceuticals, on the prohibition on sale of several combination drugs. The judge in the Delhi High court granted an interim stay to the pharmaceutical companies and said regulators should take "no coercive steps" against them.

  • Reuterslast year

    India's Glenmark bets on US sales to offset emerging markets weakness

    Indian drugmaker Glenmark Pharmaceuticals is counting on strong growth in the United States, where it will launch a dozen new medicines, to offset weakness in emerging markets this year, its chief executive said. One of India's top 10 drugmakers by sales, Glenmark has seen its profit hit in recent quarters by currency volatility in Russia, Venezuela and other emerging markets, after a steep decline in oil prices and China's devaluation of the yuan. "Our U.S. business right now is more than compensating for the hit we are taking in emerging markets," Glenn Saldanha said on the sidelines of the company's annual general meeting in Mumbai.